# EDGAR Filing Document

**Accession Number:** 0001828253
**File Stem:** 0001104659-23-011234
**Filing Date:** 2023-2
**Character Count:** 6511
**Document Hash:** b2a49a0276c504792102fe12f14ab3c5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-011234.hdr.sgml**: 20230206

**ACCESSION NUMBER**: 0001104659-23-011234

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 4

**CONFORMED PERIOD OF REPORT**: 20230206

**FILED AS OF DATE**: 20230206

**DATE AS OF CHANGE**: 20230206

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Evaxion Biotech A/S
- **CENTRAL INDEX KEY:** 0001828253
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** G7
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39950
- **FILM NUMBER:** 23591264

**BUSINESS ADDRESS:**
- **STREET 1:** BREDGADE 34E
- **CITY:** COPENHAGEN K
- **STATE:** G7
- **ZIP:** 1260
- **BUSINESS PHONE:** 4531262615

**MAIL ADDRESS:**
- **STREET 1:** BREDGADE 34E
- **CITY:** COPENHAGEN K
- **STATE:** G7
- **ZIP:** 1260

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO SECTION 13a-16 OR 15d-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of February 2023**

**Commission File Number: 001-39950**

**Evaxion Biotech A/S**

**(Exact Name of Registrant as Specified in Its Charter)**

**Dr. Neergaards Vej 5f**

**DK-2970 Hoersholm**

**Denmark**

**(Address of principal executive offices)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ⌧ Form 40-F ◻

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ◻

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ◻

**INCORPORATION BY REFERENCE**

This report on Form 6-K shall be deemed to be incorporated by reference in Evaxion Biotech A/S's registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132) and on Form F-1 (File No. 333-266050), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

**Extraordinary General Meeting**

Furnished as Exhibit 99.1 to this Report on Form 6-K is the form of Proxy for the Extraordinary General Meeting of Evaxion Biotech A/S to be held on February 21, 2023 at 5:00 pm (CET).

**Exhibits**

Exhibit <br> <u>No.</u> <u>Description</u> <br> <u>[99.1](tm235614d1_ex99-1.htm)</u> <u>[Proxy for Extraordinary General Meeting](tm235614d1_ex99-1.htm)</u>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Evaxion Biotech A/S** | **Evaxion Biotech A/S** |
| Date: February 6, 2023 | By: | /s/ Bo Karmark |
|  |  | Bo Karmark<br> Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm235614d1_ex99-1img001.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;22349 Evaxion Biotech A S VIF Proof 1 Extraordinary General Meeting of the Shareholders of Evaxion Biotech A/S Date: February 21, 2023 See Voting Instruction On Reverse Side. Please make your marks like this: x Use pen only • Mark, sign and date your Voting Instruction Form. • Detach your Voting Instruction Form. • Return your Voting Instruction Form in the postage-paid envelope provided. MAIL _____________________________________ __________________________ Please Sign Here Please Date Above _____________________________________ __________________________ Please Sign Here Please Date Above Please separate carefully at the perforation and return just this portion in the envelope provided. Authorized Signatures - This section must be completed for your instructions to be executed. EVENT # CLIENT # Extraordinary General Meeting of the Shareholders of Evaxion Biotech A/S to be held February 21, 2023 For ADR Holders as of February 3, 2023 All votes must be received by 12:00 p.m. EST on February 16, 2023. Copyright© 2023 Mediant Communications Inc. All Rights Reserved PROXY TABULATOR FOR EVAXION BIOTECH A/S P.O. BOX 8016 CARY, NC 27512-9903 Directors Recommend For Against Abstain AGENDA FOR THE GENERAL MEETING 1. Election of chairman of the meeting 2. Proposal to authorize the Board of Directors to issue investor warrants 3. Proposal to authorize the Board of Directors to increase the share capital 4. Proposal to authorize the chairman of the meeting Board Recommended FOR FOR FOR FOR 22349 Evaxion Biotech A S VIF.indd 1 1/30/2023 12:33:36 PM |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm235614d1_ex99-1img002.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;22349 Evaxion Biotech A S VIF Proof 1 Evaxion Biotech A/S Instructions to The Bank of New York Mellon, as Depositary (Must be received prior to 12:00 p.m. on February 16, 2023) The undersigned registered owner of American Depositary Receipts hereby requests and instructs The Bank of New York Mellon, as Depositary, to endeavor, in so far as practicable, to vote or cause to be voted the amount of shares or other Deposited Securities represented by such Receipt of Evaxion Biotech A/S registered in the name of the undersigned on the books of the Depositary as of the close of business on February 3, 2023 at the Extraordinary General Meeting of the Shareholders of Evaxion Biotech A/S to be held on February 21, 2023 in respect of the resolutions specified on the reverse. NOTE: Instructions as to voting on the specific resolutions should be indicated by an X in the appropriate box. If no specification is made, the Depositary will deem the undersigned to have instructed the Depositary to give a discretionary proxy to a person designated by Evaxion Biotech A/S with respect to such shares or other Deposited Securities and the Depositary will give such instruction. (Continued and to be marked, dated and signed, on the other side) PROXY TABULATOR FOR Evaxion Biotech A/S P.O. Box 8016 CARY, NC 27512-9903 22349 Evaxion Biotech A S VIF.indd 2 1/30/2023 12:33:36 PM |

---